Response to the Higher Education Funding Council's and Department of Employment and Learning Northern Ireland consultation on the Research Assessment Exercise 2008: panel configuration and recruitment.

FOREWORD

Below is the Academy of Medical Sciences response to the RAE 2008 consultation about panel configuration and recruitment. This document was prepared on behalf of the Academy by a working group chaired by Professor Peter Rigby, FMedSci and has received endorsement from the Academy’s Council.

The Academy welcomes the opportunity to respond to this consultation. This paper reinforces and elaborates on our previous response to the 2003 consultation about the review of research assessment.

SECTION 1

Stakeholders should address the proposed configuration of units of assessment and their groupings under main panels given in Annex A of the consultation document.

The Academy welcomes the decision to avoid multiple layers of panels, as was recommended in our response to the 2003 consultation. However, a very high level of organization will be required to ensure the necessary communication between the main panels and the Units of Assessment (UoAs).

The configuration of UoAs and main panels proposed in Annex A of the consultation document takes little account of the increasingly interdisciplinary nature of research and erects curious barriers between closely related subjects. We do not understand the logic of basing some UoAs on an organ system (e.g.: Cardiovascular Medicine or Neuroscience), others on a disease area (e.g.: Cancer Studies or Infection and Immunology) and yet others on an experimental approach (e.g.: Epidemiology). Much epidemiology is concerned with cardiovascular medicine, cancer and infection and is likely to be submitted to UoAs 1, 2 and 3. In this case how will their deliberations be coordinated with those of UoA 6 that is charged with considering Epidemiology?

It is highly likely that many workers undertaking genetic epidemiology will much prefer to be considered by Panel A than by the community-orientated Panel B. Similar issues arise from the allocation of the so called Pre-clinical subjects to Panel D, when much work in these subjects will be submitted to UoAs 1 to 5. Much work in Cancer Studies, Infection and Immunology and Neuroscience could equally well be submitted to UoA 15, Biological Sciences, as occurred in the last RAE. Furthermore, as is discussed later in our response, UoA 5 is so broad as to be unworkable. Given that highly related work could legitimately be submitted to different UoAs reporting to different Main Panels, the Academy finds it very hard to understand how uniform standards will be set and maintained. The proposed structure will require a very large volume of cross-referral between UoAs.

The proposed UoA 3 ‘Infection and Immunology’ is too diverse. A huge tranche of immunology has nothing to do with infection, which is itself a heterogeneous discipline. At the least great care will be needed ensuring this UoA has a balanced membership.

The fields covered by the proposed UoA 5 are very broad and a large number of advisors are likely to be required to do the topics submitted justice. After the last RAE stakeholders commented that areas such as genetics and genomic science, and developmental biology and reproductive medicine required a great deal of work. Given that the work is not likely to be reduced in the next RAE UoA 5 might run into difficulties. One solution would be to
introduce ‘molecular’ medicine and ‘physiological’ medicine UoAs in place of the proposed UoA 5. This would reduce the overall burden on this UoA and would probably be recognised by submitting centres as it is little different from the current way they seek support from the MRC and Wellcome Trust. A similar challenge is presented by UoA 9 ‘Other Community Based Clinical Subjects’ as it is currently proposed.

The Academy is greatly concerned by the allocation of dentistry and psychiatry to the community-based Panel B. For example, biological psychiatry (imaging, genetics, psychopharmacology, neurochemistry etc.) actually comprises the majority of psychiatric research in the UK which makes it better placed in a panel dealing with neuroscience, genetics or even hospital-based clinical science. Furthermore, psychology might be better placed alongside psychiatry and the neurosciences. It will therefore be crucial to ensure that, at the very least, both UoAs contain sufficient breadth of expertise to cover the more biological areas and have strong chairs, if this configuration is to be continued. We reiterate our concern about the neurosciences being split across several main panels. Everything will depend on whether cross-reference of groups to other panels will continue or if it will be in the same bracket as external advisors (see paragraphs 28 & 29 of the consultation document).

We are firmly of the view that Pharmacy should be removed from the proposed UoA 12 ‘Allied Health Professions’ and placed closer to medicine and the basic biomedical sciences, which is where it belongs.

The Academy calls upon the Funding Councils to reconsider the panel structure for biomedical sciences, in full consultation with appropriate stakeholders.

SECTION 2

Stakeholders are invited to suggest amendments or additions to the list of nominating bodies given in Annex B of the consultation document.

The Academy finds the list of nominating bodies surprising, both in terms of exclusion and inclusion. Therefore, we recommend that it should be reassessed to ensure it better reflects the stakeholder community. For example, the Academy notes with great concern the exclusion of Medical Royal Colleges (Royal College of Psychiatrists), major funders of biomedical research (Cancer Research UK and the British Heart Foundation) and large learned societies (British Societies for Cell Biology and Developmental Biology). In the Academy’s view this list should be completely reworked in consultation with the sector.

The independent Academy of Medical Sciences promotes advances in medical science and campaigns to ensure these are translated as quickly as possible into benefits for patients. The Academy’s 800 Fellows are the United Kingdom’s leading medical scientists from hospitals, academia, industry and the public service.

The Academy’s Officers are: Sir Keith Peters, FRS, PMedSci (President), Lord Turnberg, FMedSci (Vice-President), Sir John Skehel, FRS, FMedSci (Vice-President), Sir Colin Dollery, FMedSci (Treasurer) and Professor Patrick Vallance, FMedSci (Registrar). The Academy’s Executive Director is Mrs Mary Manning.

The Academy of Medical Sciences
10 Carlton House Terrace
London SW1Y 5AH

Tel.: ++44 (0) 20 7969 5288
Fax.: ++44 (0) 20 7969 5298

E-mail: apollo@acmedsci.ac.uk
Web: www.acmedsci.ac.uk

Registered charity no.: 1070618
Registered company no.: 3520281

The Academy of Medical Sciences is a company limited by guarantee.
WORKING GROUP MEMBERS

Professor Peter Rigby, FMedSci (Chair)
Chief Executive and Professor of Developmental Biology
Institute of Cancer Research

Dame Ingrid Allen, FMedSci
Professor Emeritus of Neuropathology
Queen's University Belfast

Professor Colin Bird, FMedSci
Edinburgh

Sir Leszek Borysiewicz, FMedSci
Principal
Faculty of Medicine
Imperial College of Science Technology and Medicine

Professor Jonathan Cohen, FMedSci
Dean
Brighton and Sussex Medical School

Professor David Gordon, FMedSci
Dean of the Faculty of Medicine, Dentistry, Nursing and Pharmacy
University of Manchester

Professor Keith Gull, CBE, FRS, FMedSci
Wellcome Trust Principal Research Fellow
University of Oxford

Professor Michael Owen, FMedSci
Professor of Psychological Medicine
University of Wales College of Medicine

Sir Keith Peters, FRS, PMedSci
Regius Professor of Physic
University of Cambridge

Professor Nancy Rothwell, FRS, FMedSci
MRC Research Professor
University of Manchester

Professor Stephen Smith, FMedSci
Executive Dean
Faculty of Medicine
University of Glasgow

Professor Eric Thomas, FMedSci
Vice-Chancellor
University of Bristol

Professor Anthony Weetman, FMedSci
Dean of the Medical School and Professor of Medicine
University of Sheffield

ACKNOWLEDGEMENTS

The Academy is most grateful to Professor Peter Rigby and the members of the working group for preparing this consultation response. We would also like to thank the Academy’s Officers and Council for their contributions.

DISCLAIMER

The members of the Working Group participated in the production of this response purely in an individual advisory capacity and not as representatives of, or on behalf of, their individual
affiliated hospitals, universities, organisations or associations (where indicated in the appendices). Their participation should not be taken as an endorsement by these bodies.